TNFRSF4, also known as OX40, activates the PI3K/PKB, NF-κB1 and NFAT pathways and enhances T cell-mediated antitumor immunity, thereby improving survival in several preclinical cancer models, including B16 melanoma and lung cancer (47). This evidence concerns the gene NFKB1 and melanoma.